| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Javier Fernández-Ruiz | |
| P2860 | cites work | Alzheimer's disease; taking the edge off with cannabinoids? | Q24681412 |
| Fine motor control in rats is disrupted by delta-9-tetrahydrocannabinol | Q28145410 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| The endocannabinoid system drives neural progenitor proliferation | Q28263148 | ||
| Role of CB2 receptors in neuroprotective effects of cannabinoids | Q28269610 | ||
| Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons | Q28363375 | ||
| Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 | ||
| Motor actions of cannabinoids in the basal ganglia output nuclei | Q33720160 | ||
| The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. | Q33890269 | ||
| Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide | Q48136699 | ||
| Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. | Q48217036 | ||
| Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function | Q48262881 | ||
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 | ||
| Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent | Q48332786 | ||
| Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease | Q48435185 | ||
| Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. | Q49059668 | ||
| Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. | Q51976878 | ||
| Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. | Q52060269 | ||
| Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. | Q54001516 | ||
| Parkinson's disease | Q56877819 | ||
| Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats | Q64814751 | ||
| Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice | Q71901352 | ||
| delta 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats | Q72270865 | ||
| The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons | Q72302141 | ||
| Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease | Q73304376 | ||
| Involvement of GABA(B) receptors in the motor inhibition produced by agonists of brain cannabinoid receptors | Q73554044 | ||
| Activational role of cannabinoids on movement | Q73575705 | ||
| Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor | Q73704501 | ||
| Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes | Q84093381 | ||
| Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia | Q34113369 | ||
| Cannabinoids reduce symptoms of Tourette’s syndrome | Q34266671 | ||
| Brain cannabinoid systems as targets for the therapy of neurological disorders | Q34492167 | ||
| A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol | Q34561595 | ||
| Cannabinoid control of neuroinflammation related to multiple sclerosis | Q34583231 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 | ||
| The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. | Q34786832 | ||
| Acute neuronal injury, excitotoxicity, and the endocannabinoid system | Q34995079 | ||
| A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation | Q35035844 | ||
| CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 | ||
| Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human | Q35120095 | ||
| The Endocannabinoid System and Huntingtons Disease | Q35551819 | ||
| Cannabinoid receptors and their role in neuroprotection | Q36211444 | ||
| Cannabinoid control of motor function at the basal ganglia. | Q36441208 | ||
| Cannabinoid CB2 receptor: a new target for controlling neural cell survival? | Q36671508 | ||
| The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases | Q36727554 | ||
| Biochemistry and pharmacology of endovanilloids | Q36756199 | ||
| The endocannabinoid system in targeting inflammatory neurodegenerative diseases | Q36756837 | ||
| The endocannabinoid system and neurogenesis in health and disease. | Q36778571 | ||
| Cannabinoids and neuroprotection in basal ganglia disorders. | Q36977766 | ||
| Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments | Q37209427 | ||
| Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. | Q37253331 | ||
| The endocannabinoid system in Huntington's disease. | Q37264872 | ||
| Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 | ||
| Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease | Q39365419 | ||
| Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. | Q40205916 | ||
| Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 | ||
| Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. | Q40743568 | ||
| Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. | Q40799260 | ||
| Marijuana for parkinsonian tremor | Q41369366 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease | Q42464432 | ||
| Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry | Q42471010 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice | Q42490465 | ||
| Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain | Q42493166 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. | Q42517324 | ||
| Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum | Q42523780 | ||
| Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. | Q42624110 | ||
| Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease | Q42695373 | ||
| Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. | Q43334794 | ||
| Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats | Q43425029 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. | Q43621342 | ||
| Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease | Q43669613 | ||
| Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 | ||
| Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 | ||
| Postsynaptic endocannabinoid release is critical to long-term depression in the striatum | Q43971441 | ||
| Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse | Q44084440 | ||
| UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide | Q44090402 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia | Q44209138 | ||
| Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease | Q44237885 | ||
| Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. | Q44330257 | ||
| Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism | Q44418544 | ||
| Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia | Q44451116 | ||
| Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling | Q44455990 | ||
| Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse | Q44672761 | ||
| In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake | Q44743034 | ||
| Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function | Q44793025 | ||
| Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease | Q44931450 | ||
| Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes | Q45076771 | ||
| In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity | Q45096581 | ||
| Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. | Q45217300 | ||
| Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. | Q45289172 | ||
| Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. | Q45290294 | ||
| Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice | Q45295586 | ||
| Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice | Q45297144 | ||
| UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. | Q45297533 | ||
| Nabilone increases choreatic movements in Huntington's disease | Q45299472 | ||
| A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. | Q45300340 | ||
| The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease | Q45300428 | ||
| The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. | Q45302088 | ||
| Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease | Q45305400 | ||
| Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease | Q45305788 | ||
| Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 | ||
| Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 | ||
| Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 | ||
| High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease | Q46552546 | ||
| Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications | Q46731448 | ||
| Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. | Q47242856 | ||
| Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice | Q47994629 | ||
| Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors | Q48087305 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endocannabinoid system | Q368952 |
| P304 | page(s) | 1029-1040 | |
| P577 | publication date | 2009-02-13 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | The endocannabinoid system as a target for the treatment of motor dysfunction | |
| P478 | volume | 156 |
| Q38789599 | A Single Intrathecal or Intraperitoneal Injection of CB2 Receptor Agonist Attenuates Bone Cancer Pain and Induces a Time-Dependent Modification of GRK2. |
| Q38392800 | A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. |
| Q37645138 | Adenosine receptors: expression, function and regulation |
| Q33976751 | Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia |
| Q45185178 | Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia |
| Q38809361 | Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease |
| Q35232109 | CB(1) cannabinoid receptors and their associated proteins |
| Q38012845 | Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? |
| Q42326753 | Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells |
| Q39467487 | Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide |
| Q34053352 | Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q38522769 | Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia |
| Q36155898 | Cannabinoids and Dementia: A Review of Clinical and Preclinical Data |
| Q38563981 | Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications |
| Q42258332 | Cannabinoids in Parkinson's Disease |
| Q27336419 | Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics |
| Q91775177 | Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome |
| Q37637769 | Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias |
| Q37659341 | Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis |
| Q34391577 | Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders |
| Q64811535 | Current Drugs and Potential Future Neuroprotective Compounds for Parkinson's Disease |
| Q37734563 | Dopamine and glutamate in Huntington's disease: A balancing act. |
| Q36975938 | Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. |
| Q42167232 | Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients |
| Q42844506 | Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys |
| Q38018946 | Endocannabinoid modulation of dopaminergic motor circuits. |
| Q38593124 | Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others |
| Q36686382 | Endocannabinoids in striatal plasticity |
| Q37820343 | Huntington's disease and Group I metabotropic glutamate receptors |
| Q33751118 | In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability |
| Q53533652 | Intrathecal Injection of JWH-015 Attenuates Bone Cancer Pain Via Time-Dependent Modification of Pro-inflammatory Cytokines Expression and Astrocytes Activity in Spinal Cord. |
| Q24633122 | Is lipid signaling through cannabinoid 2 receptors part of a protective system? |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q34224030 | Metabolic syndrome as a risk factor for neurological disorders. |
| Q36933683 | Modulating the endocannabinoid system in human health and disease--successes and failures |
| Q33901507 | Neurological soft signs in Tunisian patients with first-episode psychosis and relation with cannabis use |
| Q38684679 | Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation |
| Q36074595 | New insights on endocannabinoid transmission in psychomotor disorders |
| Q95416436 | Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases |
| Q38911685 | Pharmacogenetics of tardive dyskinesia: an updated review of the literature |
| Q34009116 | Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q37872326 | Prospects for cannabinoid therapies in basal ganglia disorders |
| Q30410119 | Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice |
| Q36972027 | Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systems |
| Q35014951 | Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. |
| Q37793366 | The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration |
| Q22242668 | The endocannabinoid system in normal and pathological brain ageing |
| Q38156518 | The influence of cannabinoids on generic traits of neurodegeneration |
| Q42948746 | Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism |
| Q30596478 | Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety |
| Q38951947 | l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements? |
| Q42500348 | Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. |
Search more.